Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 10Unknown 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 12Ovarian Neoplasms 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Sarcoma 7Colorectal Neoplasms 7Prostatic Neoplasms 6Fallopian Tube Neoplasms 6Neoplasm Metastasis 5Lymphoma 5Head and Neck Neoplasms 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Osteosarcoma 4Neoplasms 4Leukemia, Myeloid, Acute 4Central Nervous System Neoplasms 4Burkitt Lymphoma 4Stomach Neoplasms 3Sezary Syndrome 3Salivary Gland Neoplasms 3Rhabdoid Tumor 3Rectal Neoplasms 3Pain 3Neuroectodermal Tumors, Primitive, Peripheral 3Mycosis Fungoides 3Melanoma 3Lymphoma, T-Cell, Cutaneous 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × NETWORK × Neurotoxicity Syndromes × Clear all
NCT01492920 2014-12-31

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

GOG Foundation

Phase 3 Withdrawn
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Fatigue, Ovarian Neoplasms, Pain, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡